Search Results: keywords:"pharmaceutical industry"

  • H. R. 1476 — To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.
    Status:Introduced in House
    Words:329

    H. R. 1476 proposes an amendment to title XVIII of the Social Security Act to implement a gradual phase-in for plasma-derived products under the manufacturer discount program. This legislation, known as the “PLASMA Act,” establishes specific percentage discounts on these...

    Simple Explanation

    H. R. 1476 is about changing the rules so that people who make special medicines from plasma give smaller and smaller discounts on those medicines each year, starting from 2026. However, some medicines and companies aren't included in this change, which might make prices unfair between different groups.

  • H. R. 133 — To amend title XVIII of the Social Security Act to clarify the use of the national coverage determination process under the Medicare program.
    Status:Reported in House
    Words:549

    H.R. 133, also known as the "Mandating Exclusive Review of Individual Treatments Act" or the "MERIT Act," seeks to modify the Social Security Act related to Medicare. The legislation aims to provide clarity on the national coverage determination process by ensuring that...

    Simple Explanation

    H.R. 133 is a new rule that says Medicare should look at each medicine one by one to decide if it's needed, instead of looking at lots of medicines together at once. This helps make sure each medicine is checked carefully to see if it's helpful for people.

  • S. 5206 — To require a report on foreign investment in the pharmaceutical industry of the United States.
    Status:Introduced in Senate
    Words:598

    S. 5206 directs the Federal Trade Commission to create an annual report on foreign investments in the U.S. pharmaceutical industry. This report, to be prepared in consultation with the Secretary of Commerce, will assess how these investments impact the domestic capacity to...

    Simple Explanation

    S. 5206 is like a homework assignment for a U.S. government group to check each year who from other countries is putting money into making medicines in America, and to see if this is good or bad for keeping important medicine parts and machines here or sending them far away. They will make a simple version of what they find to show everyone online.